This event will take place twice on April 24th, 2023
First schedule: 1pm EDT / 7pm CET
Second schedule: 7pm EDT / 1am CET (+1)
This expert webinar is designed to improve knowledge around pharmaceutical treatments available for HCM management. It assists secondary healthcare professionals to:
- categorize patients into obstructive versus non-obstructive HCM and select appropriate management strategy
- integrate the latest pharmaceutical treatments for HCM into management strategies
This webinar is 60 minutes duration.
Cardiologists, echocardiographers, electrophysiologists, cardiac sonographers, cardiology nurses, nurse practitioners, registered nurses, physician assistants, pediatricians, pediatric nurses.
This activity is supported by educational grant funding from Bristol Myers Squibb and Cytokinetics. Learners may participate in this educational activity free of charge.
- Welcome and introduction to obstructive versus non-obstructive HCM
- Pharmaceutical treatment of obstructive HCM
- Pharmaceutical treatment of non-obstructive HCM
- Integrating newer therapies into current management scheme
- Q&A and closing remarks
By the end of this activity, attendees will be able to:
- outline available medications for the treatment of obstructive HCM
- outline available medications for the treatment of non-obstructive HCM
- describe appropriate management strategies and how to modify them when symptoms are refractory to one line of treatment
- explain how the latest pharmaceutical treatments for HCM can be integrated into current management strategies
This activity will provide continuing education (CE) credits for physicians, physician assistants, nurses and nurse practitioners.
Dr Martin Maron, MD, Director of the Hypertrophic Cardiomyopathy Center, Lahey Hospital, Burlington, Massachusetts, US, has received financial compensation for consulting for Cytokinetics, Imbria, Edgewise Therapeutics, and received research grants from IRhythm Technologies.
Prof Iacopo Olivotto, MD, Head of the Cardiomyopathy Unit and Associate Professor of Cardiovascular Medicine, Careggi University Hospital, Florence, Italy, has received financial compensation for consulting for Bristol Myers Squibb, Cytokinetics, Sanofi Genzyme, Takeda Shire, Amicus Therapeutics, Menarini, Chiesi Farmaceutici, Astrazeneca, Novartis, and received research grants from Bristol Myers Squibb, Sanofi Genzyme, Takeda Shire, Amicus Therapeutics, Menarini, Chiesi Farmaceutici, Boston Scientific, Bayer, Daichi-Sankyo.
AffinityCE staff, PCM Scientific staff, as well as planners and reviewers have no relevant financial interests to disclose.
Mitigation of relevant financial relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.